yingweiwo

DBIBB

Cat No.:V19245 Purity: ≥98%
DBIBB is a specific non-lipid agonist of the type 2 G protein-coupled receptor for lysophosphatidic acid (LPA2).
DBIBB
DBIBB Chemical Structure CAS No.: 1569309-92-7
Product category: New1
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
1mg
5mg
10mg
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Product Description
DBIBB is a specific non-lipid agonist of the type 2 G protein-coupled receptor for lysophosphatidic acid (LPA2). DBIBB alleviates gastrointestinal radiation syndrome, increases intestinal crypt survival and enterocyte proliferation, and reduces apoptosis. DBIBB is a candidate active molecule capable of alleviating acute radiation syndrome induced by high-dose gamma rays on the hematopoietic and gastrointestinal systems.
Physicochemical Properties
Molecular Formula
C23H20N2O6S
Molecular Weight
452.479704856873
Exact Mass
452.104
CAS #
1569309-92-7
PubChem CID
73296092
Appearance
Typically exists as solid at room temperature
Density
1.4±0.1 g/cm3
Boiling Point
710.4±70.0 °C at 760 mmHg
Flash Point
383.5±35.7 °C
Vapour Pressure
0.0±2.4 mmHg at 25°C
Index of Refraction
1.670
LogP
2.44
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
7
Rotatable Bond Count
8
Heavy Atom Count
32
Complexity
808
Defined Atom Stereocenter Count
0
SMILES
S(C1C=CC=CC=1C(=O)O)(NCCCCN1C(C2=CC=CC3=CC=CC(C1=O)=C23)=O)(=O)=O
InChi Key
POLJNARIJSROOS-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H20N2O6S/c26-21-17-10-5-7-15-8-6-11-18(20(15)17)22(27)25(21)14-4-3-13-24-32(30,31)19-12-2-1-9-16(19)23(28)29/h1-2,5-12,24H,3-4,13-14H2,(H,28,29)
Chemical Name
2-[4-(1,3-dioxobenzo[de]isoquinolin-2-yl)butylsulfamoyl]benzoic acid
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO : ≥ 100 mg/mL (~221.00 mM)
Solubility (In Vivo)
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)


Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders


Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.2100 mL 11.0502 mL 22.1004 mL
5 mM 0.4420 mL 2.2100 mL 4.4201 mL
10 mM 0.2210 mL 1.1050 mL 2.2100 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Biological Data
  • Characterization of DBIBB as an LPA2 GPCR Agonist Panel a. DBIBB docked into the LPA2 structure-based pharmacophore (Patil, et al., 2014) incorporates three features: an anionic (head group, yellow), a hydrophobic (linker), and a hydrophobic or aromatic (tail group, green). Three-dimensional spatial arrangements and the distances between the centroids are represented in solid black lines. This model also shows the nearest vicinity of DBIBB docked into the ligand pocket with key interacting residues, shown as stick models. R3.28 is a conserved residue in all EDG family LPA and S1P receptors that interacts with the LPA phosphate. Lack of this interaction abolishes binding to either ligand. Q3.29 determines the specificity for LPA versus S1P. The W5.41, F6.44, and W5.41 residues make π-π interactions with the tail group important for activation and potency. Panel b. Designation of the key structural motifs in GRI977143 that guided the design of DBIBB. The table shows the EC50/IC50, Emax/Imax values of GRI977143, DBIBB, and LPA 18:1 at LPA GPCR. *Vector controls were DKO MEF (LPA2), RH7777 (LPA1/3), CHO (LPA4), and B103 (LPA5) cells or engineered to express one human LPA receptor ortholog (in parenthesis). NE = no effect up to 10 μM of the ligand, the maximal concentration tested in the present experiments. Imax = % inhibition of the ~Emax50 LPA 18:1 response for a given receptor subtype using 10 μM of the antagonist. # Represents EC50 values for LPA 18:1. EC50 and IC50 concentration are given in μM for dose-response curves covering the 1 nM–10 μM range. For determination of IC50 values, dose-response curves were generated using an ~Emax50 concentration of LPA 18:1 for any given receptor subtype, and the ligand was co-applied in concentrations from 0.03 to 10 μM. Panel c. DBIBB enhances the clonogenic survival of IEC-6 cells. IEC-6 cells were irradiated with increasing doses of γ-irradiation from a 137Cs-source at a dose rate of 4.4 Gy/min and plated. Cultures were treated ~30 min postirradiation with 10 μM DBIBB or vehicle and surviving colonies (± SD) were counted on postirradiation day eight. (**p < 0.001 over control, n=3) Panel d. DBIBB and LPA inhibit radiation-induced caspase 3/7 activation in irradiated IEC-6 cells. IEC-6 cells were irradiated with 10 Gy at a dose rate of 4.4 Gy/min from a 137Cs source. Test compounds were added to serum-free medium 1 h after irradiation at the concentrations listed. Activity of caspases 3/7 (± SD) was measured 24 h after irradiation. Chem Biol . 2015 Feb 19;22(2):206-16.
  • DBIBB inhibits radiation- and genotoxic stress-induced apoptosis in vitro Panel a. The effect of DBIBB on radiation-induced activation of initiator caspase 8. DBIBB and LPA inhibited apoptosis in LPA2 MEF but were inactive in vector MEF. Increasing concentrations of the compounds or vehicle (3 μM BSA for LPA and 0.1% v/v DMSO for other compounds) were added to the cells 1 h after irradiation with 15 Gy at 4.4 Gy/min from a 137Cs source. Caspase 8 activation was measured 4 h postirradiation. Open bars indicate cells from vehicle-treated non-irradiated controls. Bars and data points represent the mean ± SD of at least three independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001 based on Student’s t-test in this and subsequent panels). Panel b. Effects of DBIBB and LPA on radiation-induced activation of initiator caspase 9. Experimental conditions and statistical methods were the same as in panel A. Panel c. DBIBB dose-dependently inhibits activation of executional caspases 3/7 in LPA2 MEF. Cells were treated with indicated concentrations of the DBIBB 1 h after radiation exposure and caspase activity (mean ± SD, n=3) was measured 4 h later. Panel d. Inhibition of radiation-induced DNA fragmentation by LPA and DBIBB in DKO MEF reconstituted with LPA2. DBIBB and LPA (symbols as in panel A) selectively inhibited DNA fragmentation in LPA2 MEF but showed no significant mitigative action in vector MEF cells. The ligands or vehicle was added to the cells 1 h after irradiation, and DNA fragmentation (mean ± SD, n=3) was measured 4 h after irradiation. Panel e. LPA2 MEF or vector transduced MEF cells were pretreated with LPA or DBIBB, and apoptosis was induced using 1.7 μM Adriamycin 1 h later. Caspase 3/7 activity (± SD, n=3) was measured 5 h after induction of apoptosis. **p < 0.01 and ***p < 0.001 using Student’s t-test relative to vehicle. Panel f. DBIBB and LPA reduce PARP-1 cleavage induced by γ–irradiation. Subconfluent LPA2- or Vector-MEF cells were serum-starved 1 h before the irradiation and were irradiated with 15 Gy. The cells were treated postirradiation with 10 μM DBIBB, 3 μM LPA, or vehicle (3 μM cc BSA + 0.1% DMSO). Four hours after the irradiation the samples were collected and 30 μg of cell lysates were separated on a 10 % SDS-PAGE and processed for western blotting. Note that LPA and DBIBB decreased the cleavage of PARP-1 in LPA2-MEF but failed to do so in Vector-MEF (representative of 3 experiments). Chem Biol . 2015 Feb 19;22(2):206-16.
  • DBIBB accelerates the resolution of γH2AXhigh cells following irradiation and activates the ERK1/2 prosurvival kinases Panel a. Time course of γH2AXhigh resolution in LPA2 MEF and Vector control MEF cells treated with DBIBB or vehicle. Cells were pretreated for 15 minutes with 10 μM DBIBB or vehicle (0.1 % DMSO) and irradiated with 15 Gy at 4.4 Gy/min. At times indicated the cells were stained with anti-phospho-H2AX eFluor660 and 104 events were recorded per sample using a LSR II flow cytometer. In the 30 min panel we indicate the position of the gate (black line) used in subsequent panels to identify γH2AXhigh cell subpouplations with the highes intensity of γH2AX staining. Blue lines are vehicle treated, red lines are DBIBB treated samples. Note the separation of DBIBB treated γH2AXhigh cells from vehicle treated cells and the lack of sapartaion between DBIBB and vehicle treated Vector control MEF (orange and green). Panel b. Attenuation of γ–H2AXhigh (mean ± SD, n=3) expression by DBIBB in LPA2 and vector transduced MEF using flow cytometry. This panel shows the quantification of the experiment shown in panel a. Open bars represent vehicle treated, filled bars DBIBB treated samples. Representative of n=3 experiments. Note that DBIBB accelerated the resolution of γ–H2AX expressing cells by significantly reducing γH2AXhigh cells in LPA2 MEF (red) but not in vector MEF (blue) at every time point tested. * Denotes p < 0.05 between DBIBB versus vehicle treated LPA2 MEF, # denotes p < 0.05 between DBIBB treated LPA2 versus vector transduced MEF. Panel c. DBIBB and LPA activates ERK1/2 phosphorylation and concomitantly reduce γ–H2AX levels in LPA2-MEF but not in Vector-MEF cells. Cells were irradiated and 4 h later processed for western blotting as in panel b. Note the robust ERK1/2 phosphorylation and the decreased γH2AX levels in the LPA2-MEF cells only (representative of 3 experiments). Chem Biol . 2015 Feb 19;22(2):206-16.
Contact Us